Indapta Therapeutics
Fabio Pucci is a seasoned professional in venture investments and biotechnology, currently serving as the Senior Director of Venture Investments at Leaps by Bayer since October 2021. In addition to this role, Fabio holds several board positions, including Member of the Board of Directors at Dewpoint Therapeutics, Lyterian Therapeutics, Mozart Therapeutics, Capstan Therapeutics, Indapta Therapeutics, Immunitas Therapeutics, and Boundless Bio, as well as serving as a Board Observer for Kojin Therapeutics. Fabio contributes to academia as an Adjunct Professor for the "Business of Biotechnology" master course at Northeastern University. Fabio's academic credentials include an MBA from London Business School and a PhD in Cell/Cellular and Molecular Biology from The University of Edinburgh.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Indapta Therapeutics
1 followers
Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple types of cancer.